Elsevier

Neuroscience

Volume 44, Issue 3, 1991, Pages 591-605
Neuroscience

Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey

https://doi.org/10.1016/0306-4522(91)90080-8Get rights and content

Abstract

In an attempt to define neurochemically the part played by l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a potential Parkinson's disease-inducing neurotoxin, we measured the tissue concentrations of the monoamines dopamine, noradrenaline and serotonin in 45 brain regions in nine rhesus monkeys (Macaco mulatto) receiving repeated intramuscular injections of a total amount of 2.1–7.5mg/kg MPTP-HC1. Four monkeys treated with MPTP during a period of one to five weeks developed permanent Parkinsonism, and five animals receiving the neurotoxin during a period of two to seven months remained asymptomatic. We found that, compared with the distribution pattern established in the brain of seven normal (drug-free) rhesus monkeys, in the MPTP-treated monkeys none of the three major brain monoamine neuron systems was completely resistant to the neurotoxin. In addition, each brain monoamine had a characteristic regional pattern of MPTP-induced changes. As expected, the most significant alterations were found within the nigrostriatal dopamine system, i.e. profound dopamine loss in caudate nucleus, putamen and substantia nigra. However, many extrastriatal regions of the subcortex and brainstem also suffered significant loss of dopamine, with the noradrenaline loss in the regionally subdivided brainstem being less widespread, and the serotonin levels least affected. Thus, in subcortex/brainstem the ranking order of sensitivity to MPTP was: dopamine < noradrenaline < serotonin. In the cerebral (neo- and limbic) cortex, all three monoamine neuron systems suffered widespread statistically significant losses. The ranking order of MPTP sensitivity of the cortical monoamines was: noradrenaline < serotonin < dopamine. In the cerebellar cortex, dopamine and noradrenaline concentrations were significantly reduced, whereas the serotonin level remained unchanged. A remarkable observation was that many of the subcortical and cortical changes found in the symptomatic monkeys were also found in the asymptomatic animals. Our data are compatible with several possible mechanisms by which MPTP may have produced the observed patterns of monoamine loss in the brain of the rhesus monkey.

Our study demonstrates that in the rhesus monkey MPTP mimicked, in addition to the profound striatal dopamine loss, some of the extrastriatal dopamine, noradrenaline and serotonin changes often seen in the brain of patients with idiopathic Parkinson's disease. However, using our treatment regimen, we have not been able to reproduce in the rhesus monkey the inter-regional pattern of striatal dopamine loss typical of idiopathic Parkinson's disease, i.e. a significantly greater loss of dopamine in the putamen compared with the caudate nucleus.

References (98)

  • ElsworthJ.D. et al.

    Differential responsiveness to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum

    Life Sci.

    (1987)
  • ElsworthJ.D. et al.

    Effects of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF

    Brain Res.

    (1987)
  • ElsworthJ.D. et al.

    MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate

    Neurosci. Lett.

    (1990)
  • EnzA. et al.

    Acute administration of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) reduces dopamine and serotonin but accelerates norepinephrine metabolism in the rat brain. Effect of chronic pretreatment with MPTP

    Eur. J. Pharmac.

    (1984)
  • GermanD.C. et al.

    l-Methyl-4-phenyl-l,2,3,6-tetrahydro-pyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?

    Neurocience

    (1988)
  • GibbW.R.G. et al.

    The dopamine neurotoxin l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset

    Neurosci. Lett.

    (1986)
  • Goldman-RakicP.S. et al.

    Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys

    Neuroscience

    (1981)
  • GuptaM. et al.

    MPTP alters central catecholamine neurons in addition to the nigrostriatal system

    Brain Res. Bull.

    (1984)
  • HallmanH. et al.

    Neurotoxicity of the meperidine analogue jV-methyl-4-phenyl-l,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse

    Eur. J. Pharmac.

    (1984)
  • HerkenhamM. et al.

    Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study

    Neuroscience

    (1991)
  • HinzenD. et al.

    The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment

    Eur. J. Pharmac.

    (1986)
  • ImaiH. et al.

    Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): behavior and histology

    Brain Res.

    (1988)
  • IrwinI. et al.

    The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey

    Brain Res.

    (1990)
  • JohannessenJ.N. et al.

    Differences in the metabolism of MPTP in the rodent and primate: parallel differences in sensitivity to its neurotoxic effects

    Life Sci.

    (1985)
  • KellerH.H. et al.

    Evidence for the release of l-methyl-4-phenyipyridinium (MPP+) from rat striatal neurons in vitro

    Eur. J. Pharmac.

    (1985)
  • KinemuchiH. et al.

    Participation of brain monoamine oxidase B form in the neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity

    Neurosci. Lett.

    (1985)
  • KinemuchiH. et al.

    The neurotoxicity of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson's disease

    Neurochem. Int.

    (1987)
  • KittC.A. et al.

    Injury of nigral neurons exposed to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey

    Neuroscience

    (1986)
  • MarksteinR. et al.

    Neurochemical investigations in vitro with 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) in preparations of rat brain

    Eur. J. Pharmac.

    (1984)
  • MelamedE. et al.

    In vivo effect of MPTP on monoamine oxidase activity in mouse striatum

    Brain Res.

    (1985)
  • MitchellI.J. et al.

    Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the Macaque monkey include the ventral tegmental area and the locus coeruleus

    Neurosci. Lett.

    (1985)
  • PiflCh. et al.

    Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

    Neurochem. Int.

    (1990)
  • PiflCh. et al.

    The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease

    Neurosci. Lett.

    (1988)
  • PrestonK.L. et al.

    Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain

    Brain Res.

    (1985)
  • RoseS. et al.

    Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets

    Biochem. Pharmac.

    (1989)
  • SalachJ.I. et al.

    Oxidation of the neurotoxic aminé1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP

    Biochem. biophys. Res. Commun.

    (1984)
  • SayreL.M.

    Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP)

    Toxic. Lett.

    (1989)
  • ScattonB. et al.

    Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease

    Brain Res.

    (1983)
  • SchneiderJ.S. et al.

    Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys

    Brain Res.

    (1990)
  • SchneiderJ.S. et al.

    Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP): behavior, histology, and biochemistry

    Expl Neurol.

    (1986)
  • SchneiderJ.S. et al.

    Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP

    Brain Res.

    (1987)
  • SchultzW.

    MPTP-induced Parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology

    Gen. Pharmac.

    (1988)
  • SchultzW. et al.

    Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism

    Neurosci. Lett.

    (1985)
  • ShenR.-S. et al.

    Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+

    Fedn Eur. biochem. Socs Lett.

    (1985)
  • UekiA. et al.

    Further treatment with MPTP does not produce Parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin

    Neuropharmacology

    (1989)
  • WatersC.M. et al.

    An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset

    Neuroscience

    (1987)
  • WenkG.L. et al.

    Age-related changes in multiple neurotransmitter systems in the monkey brain

    Neurobiol. Aging

    (1989)
  • ZigmondM.J. et al.

    Animal models of Parkinsonism using selective neurotoxins: clinical and basic implications

    Int. Rev. Neurobiol.

    (1989)
  • BallardP.A. et al.

    Permanent human Parkinsonism due to l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

    Neurology

    (1985)
  • Cited by (199)

    • Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine

      2021, Progress in Brain Research
      Citation Excerpt :

      The inclusion of an experimental group only injured with MDMA is required to definitely answer the question of the potential toxicity of MDMA toward the DA system. On another side, as previously shown (Masilamoni and Smith, 2018; Pifl et al., 1991), MPTP, depending on its concentration and administration regimen, can have consequences on other monoaminergic systems. In our hands, MPTP administrated acutely at high doses injures the 5-HT system at both terminals and cell bodies levels.

    • Serotonergic innervation of the striatum in a nonhuman primate model of Parkinson's disease

      2020, Neuropharmacology
      Citation Excerpt :

      The results of the present work are congruent with previous biochemical findings obtained using the same experimental protocol. HPLC analyses of striatal 5-HT and 5-HIAA showed no concentration changes in MPTP-intoxicated monkeys compared to controls (Blesa et al., 2012), coinciding with the striatal serotonin HPLC results published in other MPTP monkey models (rostral caudate and putamen in Pifl et al., 1991; caudate in Franke et al., 2016). It is relevant to point out that the PD model used here has several strengths.

    View all citing articles on Scopus
    View full text